|
Samaritan
Therapeutics Names
Entrepreneurial MD President
Wednesday February 13, 9:29
am ET
Wolfgang
Renz MD, Ph.D., to Move Samaritan Therapeutics'
Drug Candidates Forward With Health Canada, Canada's
FDA Equivalent
Return
to Homepage | See All News
Samaritan
Pharmaceuticals (OTC BB:SPHC.OB - Website)
and Samaritan Therapeutics, a Montreal research and
development biotech company, minority owned by Samaritan
Pharmaceuticals, is pleased to announce Dr. Wolfgang
Renz as President of Samaritan Therapeutics to accelerate
Samaritan Therapeutics' innovative drug pipeline forward
with Health Canada, Canada's FDA equivalent.
Dr.
Renz has over eleven years of experience in the pharmaceutical
industry including working with multinational CRO and
public pharmaceutical companies. Prior to joining Venn
Life Sciences, Dr. Renz was Vice President Clinical
Operations and Business Development, Hesperion Limited,
Switzerland. While working at ICON plc., Dr. Renz oversaw
business development in Rest of World Regions including
Latin America, South Africa, India, and Asia Pacific.
Dr.
Renz has also held increasing management positions in
clinical development and marketing at Hoffman LaRoche,
Merz, and Axcan Pharma. Dr. Renz has developed products
in several therapeutic areas including: virology, cardiology,
oncology, rheumatology, and women's health. He has clinical
and regulatory experience in drug development in Europe
and U.S.
|
| "I
am delighted Samaritan Therapeutics' Board of
Directors has confidence in me to bring its important
drug candidates through the Health Canada's drug
approval process.''
Dr.
Wolfgang Renz
President of Samaritan Therapeutics |
|
Dr. Renz
obtained his medical degree from the University of Freiburg,
Germany and completed rotations in Germany, Switzerland, and
the U.S. He is board certified in emergency medicine and has
held an Honorary Research Fellowship from the University of
London, UK. He completed his Ph.D. in Anatomy at the University
of Freiburg, Germany.
Dr. Wolfgang
Renz, President of Samaritan Therapeutics stated, "I am delighted
Samaritan Therapeutics' Board of Directors has confidence
in me to bring its important drug candidates through the Health
Canada's drug approval process.''
Dr. Renz
is currently and will retain his position as CEO of Venn Life
Sciences Canada, Ltd., a next generation clinical research
organization (CRO) that allows for fast, efficient, cost saving-management
and execution of clinical trials.
About
Samaritan Therapeutics, Montreal, Canada:
Samaritan Therapeutics, Inc. is a Canadian controlled
private Canadian company based in Montreal, Canada, that performs
its scientific research and drug development in Canada. Samaritan
Therapeutics has a research and development collaboration
with The Research Institute of McGill University Health Center
to develop new and improved innovative drugs to relieve the
suffering of patients with Alzheimer's, Cancer, Heart disease,
and Infectious disease. Samaritan Pharmaceuticals, Inc. (OTC
BB:SPHC.OB - News) is a minority shareholder and partner with
Samaritan Therapeutics, Inc. to develop innovative drug candidates
through Health Canada, Canada's FDA equivalent.
Disclaimer
The company disclaims any information created by
an outside party and endorses only information communicated
by its press releases, filings, and website. This news release
contains forward-looking statements about its minority owned
company Samaritan Therapeutics. However, as with any biopharmaceutical
under development, there are significant risks and uncertainties
in the process of development and regulatory review. There
are no guarantees that products will prove to be commercially
successful. The company undertakes no duty to update forward-looking
statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
|
